Stock analysts at B. Riley raised their FY2025 earnings per share estimates for Arrowhead Pharmaceuticals in a report issued ...
Yousif Capital Management LLC reduced its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 5.2% in the 4th quarter, according to the company in its most recent 13F filing ...
Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, ...
In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research ...
In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ ...
First Quarter 2025 Results Key Financial Results Net loss: US$173.1m ...
Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis ...
Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.